A new compound, discovered jointly by international pharmaceutical company Servier, headquartered in France, and Vernalis (R&D), a company based in the UK, has been shown by researchers at the Walter and Eliza Hall Institute and Servier to block a protein that is essential for the sustained growth of up to a quarter of all cancers.
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of blood cancers such as acute myeloid leukaemia,lymphoma and multiple myeloma, as well as solid cancers such as melanoma and cancers of the lung and breast. It is published online today in the journal Nature.
The Servier compound – S63845 – targets a protein of the BCL2 family, called MCL1, which is essential for the sustained survival of these cancer cells.
Institute scientist Associate Professor Guillaume Lessene, who led the Walter and Eliza Hall Institute’s research team in Melbourne, Australia, said the work provided the first clear preclinical evidence that inhibiting MCL1 was effective in targeting several cancer types.
“MCL1 is important for many cancers because it is a pro-survival protein that allows the cancerous cells to evade the process of programmed cell death that normally removes cancer cells from the body,” Associate Professor Lessene said. “Extensive studies performed in a variety of cancer models have shown that S63845 potently targets cancer cells dependent on MCL1 for their survival.”
The institute team of Associate Professor Lessene worked with haematologist Associate Professor Andrew Wei and Dr Donia Moujalled from The Alfred Hospital and Servier scientists, to demonstrate that not only was S63845 effective against several cancer types, but that it could also be delivered at doses that were well tolerated by normal cells.
Dr Olivier Geneste, Director of Oncology Research at Servier, said this preclinical research represented major findings regarding the druggability of MCL1, a valuable and highly challenging target. “S63845 was discovered through collaboration with the fragment and structure based discovery expertise at Vernalis,” he said. “As part of the ongoing Servier / Novartis collaboration on this target class, clinical development of a MCL1 inhibitor should be launched in the near future.”
Associate Professor Lessene said the research provided further evidence of the usefulness of a new class of anti-cancer drugs called BH3 mimetics. “BH3 mimetics inhibit a group of proteins known as the ‘pro-survival BCL-2 proteins’,” he said. “MCL1 is a member of this protein family, and inhibiting it activates the process of programmed cell death. Walter and Eliza Hall Institute researchers revealed the role of BCL-2 in cancer more than 28 years ago and the essential role of MCL1 for the survival of malignant cells four years ago.”
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
- Achilles’ heel of pancreatic cancer may lead to improved patient treatment on April 17, 2019 at 9:14 pm
Scientists may have discovered the “Achilles’ heel” of pancreatic cancer – a condition which is notoriously difficult to treat. Researchers believe a protein called leukaemia inhibitory factor (LIF) ... […]
- Alex Trebek Gives Promising Update on Cancer Treatment, Will Return for 'Jeopardy!' Season 36 on April 17, 2019 at 7:11 pm
The iconic host of Jeopardy! worried fans earlier this year when he revealed a serious health scare. Taking to social media, Alex Trebek revealed that he was diagnosed with stage 4 pancreatic ... […]
- Alex Trebek Says He’s “Feeling Good,” Continuing Cancer Treatment, Looks Forward To September Return on April 17, 2019 at 7:10 pm
Promising to see viewers with the September return of the game show’s 36th season – but also pledging honesty about his condition – Trebek said, “Some of you may recall that at the beginning of this ... […]
- SK Biopharmaceuticals and twoXAR Sign Collaboration Agreement to Discover and Develop First-In-Class Treatments for Non-Small Cell Lung Cancer on April 17, 2019 at 5:54 pm
PANGYO, South Korea & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Apr 17, 2019--SK Biopharmaceuticals, a pharmaceutical company focused on disorders of central nervous system and cancer, and twoXAR, Inc., ... […]
- Alex Trebek reassures 'Jeopardy!' fans about his health during cancer treatment: 'I'm feeling good' on April 17, 2019 at 3:40 pm
Jeopardy! fans were relieved Wednesday to hear a positive health update from the show’s longtime host, Alex Trebek. The 78-year-old, who has been the face of the show since 1984, said in a video ... […]
- New study targets Achilles' heel of pancreatic cancer, with promising results on April 17, 2019 at 10:02 am
Additionally, tumor cells are encased in a "protective shield," a microenvironment conferring resistance to many cancer treatment drugs. Now, Salk Institute researchers, along with an ... […]
- Beverley Craven: Tour return is 'prize' after cancer treatment on April 17, 2019 at 8:49 am
Beverley Craven says going back on tour with fellow singers Julia Fordham and Judie Tzuke is her reward after months of arduous cancer treatment. "It's been what's kept me going," she told the BBC. ... […]
- Researchers identify a new biomarker for personalised treatments against cancer on April 17, 2019 at 6:30 am
Cancer cells are characterised by the ability to evade apoptosis, a type of programmed cell death that allows the organism to remove damaged cells. Many studies devoted to new chemotherapy ... […]
- Alternative therapies for cancer: Do they do more harm than good? on April 16, 2019 at 11:10 am
suggesting that they may interfere with conventional cancer treatment. In 2018, the National Cancer Institute estimated that 1,735,350 people in the United States would receive a diagnosis of cancer ... […]
via Bing News